BR112015022490A2 - métodos e composições para classificação de amostras - Google Patents

métodos e composições para classificação de amostras

Info

Publication number
BR112015022490A2
BR112015022490A2 BR112015022490A BR112015022490A BR112015022490A2 BR 112015022490 A2 BR112015022490 A2 BR 112015022490A2 BR 112015022490 A BR112015022490 A BR 112015022490A BR 112015022490 A BR112015022490 A BR 112015022490A BR 112015022490 A2 BR112015022490 A2 BR 112015022490A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
sample classification
sorting samples
kits
Prior art date
Application number
BR112015022490A
Other languages
English (en)
Inventor
Barbacioru Catalin
Pankratz Daniel
Chudova Darya
C Kennedy Giulia
I Wilde Jonathan
Pagan Moraima
Sean Walsh P
Original Assignee
Veracyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veracyte Inc filed Critical Veracyte Inc
Publication of BR112015022490A2 publication Critical patent/BR112015022490A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

resumo “métodos e composições para classificação de amostras” são aqui descritos kits, composições e métodos relacionados à classificação de amostras. os métodos aqui descritos também podem ser utilizados para diagnosticar condições e para apoiar decisões relacionadas ao tratamento.
BR112015022490A 2013-03-15 2014-03-13 métodos e composições para classificação de amostras BR112015022490A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798941P 2013-03-15 2013-03-15
PCT/US2014/026411 WO2014151764A2 (en) 2013-03-15 2014-03-13 Methods and compositions for classification of samples

Publications (1)

Publication Number Publication Date
BR112015022490A2 true BR112015022490A2 (pt) 2017-07-18

Family

ID=51581658

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022490A BR112015022490A2 (pt) 2013-03-15 2014-03-13 métodos e composições para classificação de amostras

Country Status (8)

Country Link
US (1) US20160068915A1 (pt)
EP (1) EP2971164B1 (pt)
CN (1) CN105378104A (pt)
BR (1) BR112015022490A2 (pt)
GB (1) GB2525804B (pt)
IL (1) IL240512B (pt)
SG (1) SG11201506723XA (pt)
WO (1) WO2014151764A2 (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP2291553A4 (en) 2008-05-28 2011-12-14 Genomedx Biosciences Inc SYSTEMS AND METHODS FOR THE EXPRESSION-BASED DISTINCTION OF DIFFERENT CLINICAL ILLICIT STADIAS IN PROSTATE CANCER
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
CA2858581A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
DK3435084T3 (da) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res Prostatakræftprognose under anvendelse af biomarkører
WO2018048960A1 (en) * 2016-09-07 2018-03-15 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP3066219B1 (en) * 2013-11-08 2018-12-26 Ionis Pharmaceuticals, Inc. Methods for detecting oligonucleotides
JP7356788B2 (ja) 2014-11-05 2023-10-05 ベラサイト インコーポレイテッド 機械学習および高次元転写データを使用して経気管支生検における特発性肺線維症を診断するシステムおよび方法
WO2016139534A2 (en) * 2015-03-02 2016-09-09 Strand Life Sciences Private Limited Apparatuses and methods for determining a patient's response to multiple cancer drugs
WO2017065959A2 (en) * 2015-09-25 2017-04-20 Veracyte, Inc. Methods and compositions that utilize transcriptome sequencing data in machine learning-based classification
WO2017106663A1 (en) * 2015-12-18 2017-06-22 Pioneer Hi-Bred International, Inc. Methods for identification of novel genes for modulating plant agronomic traits
JP6719724B2 (ja) * 2016-02-05 2020-07-08 富士ゼロックス株式会社 データ分類装置およびプログラム
GB2555765A (en) * 2016-05-01 2018-05-16 Genome Res Ltd Method of detecting a mutational signature in a sample
CN110506127B (zh) 2016-08-24 2024-01-12 维拉科特Sd公司 基因组标签预测***癌患者对术后放射疗法应答性的用途
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CN106709267A (zh) * 2017-01-25 2017-05-24 武汉贝纳科技服务有限公司 数据获取方法及装置
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
US20200202171A1 (en) * 2017-05-14 2020-06-25 Digital Reasoning Systems, Inc. Systems and methods for rapidly building, managing, and sharing machine learning models
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019014647A1 (en) * 2017-07-14 2019-01-17 Cofactor Genomics, Inc. IMMUNO-ONCOLOGIC APPLICATIONS USING NEXT GENERATION SEQUENCING
CN110019990B (zh) * 2017-07-14 2023-05-23 阿里巴巴集团控股有限公司 样本筛选的方法和装置、业务对象数据搜索的方法和装置
WO2019023517A2 (en) * 2017-07-27 2019-01-31 Veracyte, Inc. GENOMIC SEQUENCING CLASSIFIER
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CN111032885B (zh) * 2017-09-07 2024-05-17 深圳华大基因股份有限公司 一种hpv精确分型的生物信息学分析方法及***
SG10202108020VA (en) 2017-10-16 2021-09-29 Illumina Inc Deep learning-based techniques for training deep convolutional neural networks
US11861491B2 (en) 2017-10-16 2024-01-02 Illumina, Inc. Deep learning-based pathogenicity classifier for promoter single nucleotide variants (pSNVs)
CN112074909B (zh) * 2017-10-17 2024-03-19 英维特公司 变体解释终端***
US10514890B2 (en) 2017-11-15 2019-12-24 Accenture Global Solutions Limited Test case and data selection using a sampling methodology
US10409553B2 (en) 2017-11-15 2019-09-10 Accenture Global Solutions Limited Optimized construction of a sample imprint for selecting a sample dataset for comparison testing
US10241903B1 (en) * 2017-11-15 2019-03-26 Accenture Global Solutions Limited Parallel testing and reporting system
CN107798390B (zh) 2017-11-22 2023-03-21 创新先进技术有限公司 一种机器学习模型的训练方法、装置以及电子设备
CN108486098B (zh) * 2018-03-06 2021-07-06 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种用SLFN13从总RNA中纯化总mRNA的方法
SG11202009696WA (en) 2018-04-13 2020-10-29 Freenome Holdings Inc Machine learning implementation for multi-analyte assay of biological samples
CN108359735B (zh) * 2018-05-19 2020-12-25 华中农业大学 与母猪肢蹄骨密度相关的vtcn1基因的snp遗传标记
CN108588223B (zh) * 2018-06-11 2021-10-15 北京大学人民医院 定量检测s100a16基因表达的引物和探针及其应用
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3103385A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
WO2020041204A1 (en) * 2018-08-18 2020-02-27 Sf17 Therapeutics, Inc. Artificial intelligence analysis of rna transcriptome for drug discovery
CN109411015B (zh) * 2018-09-28 2020-12-22 深圳裕策生物科技有限公司 基于循环肿瘤dna的肿瘤突变负荷检测装置及存储介质
CN109272056B (zh) * 2018-10-30 2021-09-21 成都信息工程大学 基于伪负样本的数据平衡方法及提高数据分类性能的方法
WO2020136133A1 (en) * 2018-12-23 2020-07-02 F. Hoffmann-La Roche Ag Tumor classification based on predicted tumor mutational burden
WO2020150563A1 (en) * 2019-01-17 2020-07-23 University Of Pittsburgh-Of The Commonwealth System Of Higher Education A diagnostic and prognostic test for multiple cancer types based on transcript profiling
CN110084314B (zh) * 2019-05-06 2021-08-13 西安交通大学 一种针对靶向捕获基因测序数据的假阳性基因突变过滤方法
US20220213558A1 (en) * 2019-05-31 2022-07-07 Convergent Genomics, Inc. Methods and systems for urine-based detection of urologic conditions
US11948684B2 (en) * 2019-06-20 2024-04-02 Latha Chakravarthy Diagnostic process for disease detection using gene expression based multi layer PCA classifier
CN110218796B (zh) * 2019-06-27 2020-01-17 江门市中心医院 用于乳腺癌骨转移诊疗的新靶标pcdhb2
CN110706749B (zh) * 2019-09-10 2022-06-10 至本医疗科技（上海）有限公司 一种基于组织器官分化层次关系的癌症类型预测***和方法
WO2021113750A1 (en) * 2019-12-05 2021-06-10 Nooma Bio, Inc. Multi-pore device with material sorting applications
CN111383221B (zh) * 2020-03-12 2023-04-28 南方科技大学 一种脊柱侧弯检测模型的生成方法和计算机设备
US11610645B2 (en) 2020-04-30 2023-03-21 Optum Services (Ireland) Limited Cross-variant polygenic predictive data analysis
US11967430B2 (en) 2020-04-30 2024-04-23 Optum Services (Ireland) Limited Cross-variant polygenic predictive data analysis
US11978532B2 (en) 2020-04-30 2024-05-07 Optum Services (Ireland) Limited Cross-variant polygenic predictive data analysis
US11574738B2 (en) 2020-04-30 2023-02-07 Optum Services (Ireland) Limited Cross-variant polygenic predictive data analysis
US11482302B2 (en) 2020-04-30 2022-10-25 Optum Services (Ireland) Limited Cross-variant polygenic predictive data analysis
CN114438201A (zh) * 2020-11-05 2022-05-06 复旦大学附属华山医院 一种肿瘤标志物组合及其应用
CA3201235A1 (en) * 2020-12-14 2022-06-23 Christopher Douville Signal
CN112662769B (zh) * 2020-12-25 2023-03-24 中山大学 丝氨酸整合因子2在mll融合基因白血病中的应用
CN114645094B (zh) * 2022-03-21 2023-10-20 武汉凯德维斯生物技术有限公司 一种子宫内膜癌的生物标志物及其应用
CN114717338B (zh) * 2022-05-26 2023-07-14 甘肃润牧生物工程有限责任公司 一种湖羊slc27a6基因snp的检测方法及其在肉质性状早期筛选中的应用
CN115547414B (zh) * 2022-10-25 2023-04-14 黑龙江金域医学检验实验室有限公司 潜在毒力因子的确定方法、装置、计算机设备及存储介质
CN115386630B (zh) * 2022-10-31 2023-02-03 北京大学第一医院 一种用于抗血栓药物治疗血栓疗效预测的snp标志物及其应用
CN115966259B (zh) * 2022-12-26 2023-10-13 南京普恩瑞生物科技有限公司 一种基于逻辑回归建模的样本同源性检测校验方法及***

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT277936B (de) 1968-02-27 1970-01-12 Guenter Dipl Ing Knapp Verfahren zur quantitativen Bestimmung von Jod und von Schilddrüsenhormonen sowie Vorrichtung zur Durchführung des Verfahrens
US5798257A (en) 1990-07-09 1998-08-25 Research Corporation Technologies, Inc. Nucleic acid encoding human MTS-1 protein
US20020076735A1 (en) * 1998-09-25 2002-06-20 Williams Lewis T. Diagnostic and therapeutic methods using molecules differentially expressed in cancer cells
KR100501550B1 (ko) 1998-06-08 2005-07-18 후소 야쿠힝 고교 가부시끼가이샤 Ｌａｒ 포스파타제 서브유닛에 대한 항체
US6436642B1 (en) 1999-04-20 2002-08-20 Curagen Corporation Method of classifying a thyroid carcinoma using differential gene expression
US7244559B2 (en) 1999-09-16 2007-07-17 454 Life Sciences Corporation Method of sequencing a nucleic acid
US7211390B2 (en) 1999-09-16 2007-05-01 454 Life Sciences Corporation Method of sequencing a nucleic acid
US7361488B2 (en) 2000-02-07 2008-04-22 Illumina, Inc. Nucleic acid detection methods using universal priming
US6988040B2 (en) 2001-01-11 2006-01-17 Affymetrix, Inc. System, method, and computer software for genotyping analysis and identification of allelic imbalance
US20030190602A1 (en) 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US20030105320A1 (en) 2001-08-31 2003-06-05 Becker Michael M. Affinity-shifted probes for quantifying analyte polynucleotides
US20030186248A1 (en) 2002-03-29 2003-10-02 Erlander Mark G. Interpreting cytological specimens via molecular histological signatures
US7300788B2 (en) 2002-10-08 2007-11-27 Affymetrix, Inc. Method for genotyping polymorphisms in humans
US20050266443A1 (en) 2002-10-11 2005-12-01 Thomas Jefferson University Novel tumor suppressor gene and compositions and methods for making and using the same
DE60321961D1 (de) 2002-11-07 2008-08-14 Yoichi Matsubara Verfahren zum genmutationsnachweis
DE602004026033D1 (de) 2003-01-29 2010-04-29 454 Corp Zweiendige sequenzierung
US7378233B2 (en) 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
EP2295604B1 (en) 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
US7319011B2 (en) 2004-04-08 2008-01-15 Duke University Method for distinguishing follicular thyroid adenoma (FTA) from follicular thyroid carcinoma (FTC)
EP1771563A2 (en) 2004-05-28 2007-04-11 Ambion, Inc. METHODS AND COMPOSITIONS INVOLVING MicroRNA
US20060088851A1 (en) 2004-06-04 2006-04-27 Arcturus Bioscience, Inc. Invasion/migration gene
US20060019615A1 (en) 2004-07-24 2006-01-26 Ditmer Larry R Wireless keying for a continuous wave (CW) amateur radio transmitter
EP1778872A2 (en) 2004-08-11 2007-05-02 The Cleveland Clinic Foundation Method of detecting thyroid cancer
WO2006042237A2 (en) 2004-10-06 2006-04-20 Mayo Foundation For Medical Education And Research B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
US20070020657A1 (en) 2005-05-20 2007-01-25 Grebe Stefan K Methods for detecting circulating tumor cells
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
US7598052B2 (en) 2005-10-11 2009-10-06 The Regents Of The University Of Michigan Expression profile of thyroid cancer
JP4867018B2 (ja) 2006-03-22 2012-02-01 富士フイルム株式会社 癌の検出方法および抑制方法
JP6257125B2 (ja) * 2008-11-17 2018-01-10 ベラサイト インコーポレイテッド 疾患診断のための分子プロファイリングの方法および組成物
JP6078339B2 (ja) * 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
US20130231258A1 (en) * 2011-12-09 2013-09-05 Veracyte, Inc. Methods and Compositions for Classification of Samples
CN106498076A (zh) * 2010-05-11 2017-03-15 威拉赛特公司 用于诊断病状的方法和组合物

Also Published As

Publication number Publication date
GB2525804A (en) 2015-11-04
EP2971164A2 (en) 2016-01-20
SG11201506723XA (en) 2015-09-29
IL240512B (en) 2019-10-31
WO2014151764A3 (en) 2015-06-11
US20160068915A1 (en) 2016-03-10
IL240512A0 (en) 2015-10-29
CN105378104A (zh) 2016-03-02
WO2014151764A2 (en) 2014-09-25
GB201515291D0 (en) 2015-10-14
EP2971164A4 (en) 2016-11-09
GB2525804B (en) 2020-08-05
EP2971164B1 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
BR112015022490A2 (pt) métodos e composições para classificação de amostras
CL2018001156A1 (es) Preparación de muestras para muestras difíciles.
WO2014144822A3 (en) Methods and compositions for tagging and analyzing samples
BR112017020054A2 (pt) anticorpos para icos
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
JOP20170041B1 (ar) اجسام مضادة ضد vista (b7h5)
WO2013086429A3 (en) Methods and compositions for classification of samples
EA201992001A1 (ru) Композиции и способы повышения экспрессии генов
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2016016904A (es) Analisis de secuencias de acidos nucleicos.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
TR201900776T4 (tr) Memeli hücre kültürlerinin hasadına ilişkin yöntem.
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
EP3161161A4 (en) Methods and compositions for sample analysis
BR112014018995A2 (pt) Sistemas para executar ensaio automatizado
MX2016010360A (es) Moleculas de anticuerpo para el virus del dengue y uso de las mismas.
MX2022003704A (es) Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
EP3353354A4 (en) MEANS FOR COLLECTING, SAMPLING, AND DIAGNOSING SEASON SAMPLES AND ASSOCIATED METHODS
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
EP3176268A4 (en) Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
EP3523639A4 (en) DETECTION REAGENTS AND ELECTRODE ARRANGEMENTS FOR DIAGNOSTIC MULTIANALYTE TEST ELEMENTS AND METHOD FOR USE THEREOF
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
BR112018073660A2 (pt) anticorpos anti-fator ix pádua

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: VERACYTE, INC. (US)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.